The weekly litigation news digest is live. Subscribe now

IP Verse

Use Of A Vegf Antagonist To Treat Angiogenic Eye Disorders - EP3716992

The patent EP3716992 was granted to Regeneron Pharmaceuticals on Aug 10, 2022. The application was filed on Nov 29, 2018 under application number EP18825837A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3716992

REGENERON PHARMACEUTICALS
Application Number
EP18825837A
Filing Date
Nov 29, 2018
Status
Granted And Under Opposition
Jul 8, 2022
Publication Date
Aug 10, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
AMGENMay 10, 2023SCHIWECK WEINZIERL KOCH PATENTANWALTE PARTNERSCHAFT MBBADMISSIBLE
MAIWALDMay 10, 2023MAIWALDWITHDRAWN
BOULT WADE TENNANTMay 9, 2023BOULT WADE TENNANTADMISSIBLE
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBMay 5, 2023WICHMANNADMISSIBLE

Patent Citations (15) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2007190058
DESCRIPTIONUS7087411
DESCRIPTIONUS7300563
DESCRIPTIONUS7303746
DESCRIPTIONUS7303748
DESCRIPTIONUS7306799
DESCRIPTIONUS7396664
DESCRIPTIONWO0075319
INTERNATIONAL-SEARCH-REPORTUS2005260203
INTERNATIONAL-SEARCH-REPORTWO2012097019
INTERNATIONAL-SEARCH-REPORTWO2014203183
OPPOSITIONUS2013295094
OPPOSITIONUS9254338
OPPOSITIONWO2017053807
OPPOSITIONWO2019108770

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents